Biogena Group Invest AG (WBO:BIO) Other Current Receivables: €1.32 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:BIO Biogena Group Invest AG WBO:BIO
62 GF Score
Price €5.30
GF Value €3.50
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogena Group Invest AG Other Current Receivables?

Biogena Group Invest AG WBO:BIO 62 Other Current Receivables is €1.32 Mil as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 62/100 and a GF Value™ of €3.50 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Biogena Group Invest AG's Other Current Receivables for the quarter that ended in Jan. 2026 was €1.32 Mil.

Biogena Group Invest AG's quarterly Other Current Receivables increased from Jan. 2024 (€1.32 Mil) to Jan. 2025 (€1.41 Mil) but then stayed the same from Jan. 2025 (€1.41 Mil) to Jan. 2026 (€1.32 Mil).

Biogena Group Invest AG's annual Other Current Receivables increased from Jan. 2024 (€1.32 Mil) to Jan. 2025 (€1.41 Mil) but then declined from Jan. 2025 (€1.41 Mil) to Jan. 2026 (€1.32 Mil).

Biogena Group Invest AG Other Current Receivables Related Terms

Biogena Group Invest AG Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Biogena Group Invest AG's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogena Group Invest AG Other Current Receivables Chart

Biogena Group Invest AG Annual Data
Trend Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Other Current Receivables
Get a 7-Day Free Trial 0.89 1.10 1.32 1.41 1.32

Biogena Group Invest AG Semi-Annual Data
Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Other Current Receivables Get a 7-Day Free Trial 0.89 1.10 1.32 1.41 1.32
WBO:BIO
62GF Score
Biogena Group Invest AG WBO:BIO
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogena Group Invest AG Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €1.32 Mil mean?
Biogena Group Invest AG (WBO:BIO) has a Other Current Receivables of €1.32 Mil as of Jan. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Biogena Group Invest AG and its competitors.
Is Biogena Group Invest AG's Other Current Receivables too high?
Biogena Group Invest AG's current Other Current Receivables is €1.32 Mil. Overall, Biogena Group Invest AG has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Other Current Receivables compare to KHC and GIS?
Biogena Group Invest AG's Other Current Receivables of €1.32 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Consumer Packaged Goods company?
A good Other Current Receivables depends on the Consumer Packaged Goods industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Biogena Group Invest AG and its competitors. Biogena Group Invest AG's current Other Current Receivables is €1.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.50, compared to a current price of €5.30 — trading 51.4% above its estimated fair value. The current Other Current Receivables is €1.32 Mil. Biogena Group Invest AG's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Other Current Receivables is €1.32 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued. The current stock price of €5.30 is trading 51.4% above its estimated GF Value™ of €3.50. GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.

Key valuation signals for WBO:BIO:

  • Other Current Receivables: €1.32 Mil
  • GF Value™: €3.50 vs. price of €5.30 (51.4% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogena Group Invest AG Business Description

Address Strubergasse 24, Salzburg, AUT, 5020
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
62GF Score

Get the complete analysis for WBO:BIO

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.30
Price
€3.50
GF Value